➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Harvard Business School
Johnson and Johnson
Mallinckrodt
Moodys

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Patent: 5,714,313

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,714,313
Title: Simple method for detecting inhibitors of retroviral replication
Abstract:The present invention relates, in general, to a DNA segment. In particular, the present invention relates to a DNA segment comprising a selectable marker gene, a DNA segment comprising a selectable marker gene inserted into a retrotransposon, cells containing these DNA segments, and methods of using these DNA segments and cells. The present invention further relates to a vector comprising a selectable marker gene inserted into a retrotransposon, wherein the retrotransposon comprises a retroviral reverse transcriptase/RNase H gene domain and wherein the selectable marker gene contains an intron inserted into a coding sequence of the marker gene and the intron is in antisense orientation relative to transcription of the marker gene and in sense orientation relative to transcription of the retrotransposon.
Inventor(s): Garfinkel; David J. (Frederick, MD), Nissley; Dwight V. (Frederick, MD), Curcio; Joan M. (Albany, NY), Strathern; Jeffrey N. (Frederick, MD)
Assignee: United States of America as represented by the Department of Health and (Washington, DC)
Application Number:08/449,207
Patent Claims:see list of patent claims

Details for Patent 5,714,313

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial United States of America as represented by the Department of Health and (Washington, DC) 2015-02-03 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial United States of America as represented by the Department of Health and (Washington, DC) 2015-02-03 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial United States of America as represented by the Department of Health and (Washington, DC) 2015-02-03 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Dow
McKinsey
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.